AC-262536: The Underground SARM You're About to Hear a Lot More About

Ostarine has been the default "starter SARM" for over a decade. Low suppression, decent results, mountains of anecdotal data. But there's a compound sitting in the shadows that offers a fundamentally different selectivity profile — one that may deliver a better risk-to-reward ratio for specific goals. AC-262536 is a partial androgen receptor agonist with approximately 66% of testosterone's anabolic activity but only 27% of its androgenic activity in preclinical models. That ratio matters more than most people realize.

Developed by Acadia Pharmaceuticals in the mid-2000s, AC-262536 never advanced past preclinical research. But in the past 18 months, it has gained significant traction in the biohacking and SARMs community — particularly among users who want androgen receptor activation without the aggressive HPTA suppression that comes with full agonists like LGD-4033 or RAD-140.

Here's the full picture: mechanism, dosage protocols, real-world reports, and how it compares to what you're probably already using.

What Is AC-262536? The Pharmacology

AC-262536 is a non-steroidal selective androgen receptor modulator (SARM) that functions as a partial agonist at the androgen receptor (AR). This distinction — partial vs. full agonist — is the entire reason this compound exists in a meaningfully different category than most SARMs on the market.

Full Agonist vs. Partial Agonist

A full agonist binds to the androgen receptor and activates it to 100% of its maximal capacity. Testosterone is a full agonist. RAD-140 approaches full agonism. LGD-4033 is close to full agonism in muscle tissue.

A partial agonist binds to the same receptor but only activates it to a fraction of maximal capacity — even at saturating concentrations. AC-262536 maxes out at approximately 66% of testosterone's anabolic response in the levator ani muscle assay (1).

Why does this matter? Because in the presence of endogenous testosterone, a partial agonist actually competes with the stronger endogenous signal without fully replacing it. This creates a ceiling effect that limits both the upside (gains) and the downside (suppression). It's a fundamentally more conservative pharmacological approach.

The Selectivity Ratio

The critical number for any SARM is its anabolic-to-androgenic ratio. AC-262536 delivers:

• 66% anabolic activity relative to testosterone (levator ani muscle)
• 27% androgenic activity relative to testosterone (prostate)

This yields an anabolic:androgenic ratio of approximately 2.45:1. For comparison, testosterone is 1:1 by definition. Ostarine achieves roughly 3:1 in some models. RAD-140 achieves up to 90:1 in certain assays (though this doesn't translate linearly to human experience).

The practical implication: AC-262536 provides muscle-building stimulus while exerting substantially less pressure on the prostate, sebaceous glands (acne), and hair follicles than equivalent anabolic effect from testosterone.

[Internal Link: /ac-262536/]

How AC-262536 Works in the Body

Receptor Binding Dynamics

AC-262536 binds to the androgen receptor with a Ki (inhibition constant) of approximately 70 nM (2). This represents moderate binding affinity — not as tight as RAD-140 (Ki ~7 nM) but sufficient for meaningful biological activity at practical doses.

Once bound, AC-262536 induces a conformational change in the androgen receptor that is subtly different from full agonists. The receptor still translocates to the nucleus, still binds to androgen response elements (AREs), and still recruits coactivator proteins — but the recruitment is incomplete. Specific coactivators like SRC-1 and SRC-3 are recruited less efficiently, resulting in a submaximal transcriptional response (3).

Tissue Selectivity

Like other SARMs, AC-262536 demonstrates tissue-selective pharmacology:

• Skeletal muscle: Moderate anabolic activity (~66% of testosterone)
• Prostate: Reduced androgenic activity (~27% of testosterone)
• Bone: Partial agonist activity (supports bone density without aggressive stimulation)
• Liver: Minimal first-pass activation (unlike methylated oral steroids)

This selectivity is not perfectly clean — no SARM achieves zero androgenic activity in non-target tissues. But the ratio is favorable enough that practical suppression is meaningfully lower than full agonists.

Suppression Mechanism

At the hypothalamic level, partial agonism means weaker negative feedback signaling. The hypothalamus monitors androgen receptor activation to calibrate GnRH pulse frequency. A full agonist screams "we have enough testosterone" and slams LH/FSH down hard. A partial agonist whispers it — producing some suppression but not the near-complete shutdown seen with compounds like RAD-140 at higher doses.

Community blood work reports suggest LH suppression of 15-30% from baseline at typical AC-262536 doses, compared to 40-70%+ with full agonist SARMs at comparable muscle-building doses.

AC-262536 Dosage: Community Protocols

No human clinical trials exist for AC-262536. All dosage data comes from community experimentation and allometric scaling from animal studies.

Dose Ranges Reported

Administration

AC-262536 is administered orally. Most users take it once daily in the morning with or without food. The compound appears to have reasonable oral bioavailability, though precise human pharmacokinetic data has not been published.

The half-life is estimated at 12-16 hours based on community experience with dose timing experiments. Some users opt for twice-daily dosing (split AM/PM) at the upper dose ranges to maintain more stable blood levels.

Cycle Length

Most reports suggest 8-12 weeks as optimal. Effects become noticeable by week 2-3, with progressive improvement through weeks 8-10. Beyond 12 weeks, diminishing returns are common as the body adapts.

PCT Considerations

Due to the partial agonist profile and mild suppression, many users do not run formal PCT after AC-262536 cycles. However, conservative practitioners recommend a 4-week mini-PCT with over-the-counter testosterone support (Ashwagandha, Fadogia agrestis, Tongkat Ali) and monitoring recovery via blood work.

Users who stack AC-262536 with other SARMs should PCT based on the most suppressive compound in the stack.

AC-262536 vs Ostarine (MK-2866): The Comparison Everyone Wants

Ostarine has been the gold standard "mild SARM" for years. How does AC-262536 actually compare?

Mechanism

• Ostarine: Non-steroidal SARM, full-to-near-full agonist in muscle tissue, moderate selectivity
• AC-262536: Non-steroidal SARM, partial agonist, moderate selectivity with slightly lower androgenic pressure

Anabolic Potency

Ostarine is likely more potent per milligram for pure muscle accrual. Human data (from the GTx clinical trials) shows Ostarine produces measurable lean body mass gains at 3 mg/day. AC-262536 likely requires 20-30 mg/day for comparable effects based on relative receptor binding affinity and efficacy data.

Suppression

This is where AC-262536 may shine. Ostarine at 25 mg/day for 12 weeks typically suppresses testosterone by 30-50% in blood work reports. AC-262536 at comparable anabolic-effect doses appears to produce 15-30% suppression. For users who prioritize hormonal preservation, this difference is meaningful.

Side Effects

Ostarine at higher doses (25+ mg) has been associated with:

• Noticeable testosterone suppression
• Occasional hair shedding
• HDL cholesterol reduction of 10-20%

AC-262536 community reports suggest:

• Milder suppression at equivalent effect doses
• Less frequent hair shedding reports
• Comparable HDL impact (needs more data)

Who Should Choose Which?

• Choose Ostarine if: You want proven, well-documented results and are comfortable with moderate suppression. You have specific lean mass goals and want the most data-backed option.
• Choose AC-262536 if: You prioritize minimal suppression, are in a maintenance/recomp phase where slight gains plus preservation is the goal, or you want to stack a mild SARM that won't compound heavily onto other compounds' suppression.

[Internal Link: /ostarine-mk-2866/] [Internal Link: /ac-262536/]

Real-World Results: What Users Report

Body Composition

At 20-30 mg/day for 8-12 weeks, users commonly report:

• 3-6 lbs of lean mass gain (in caloric surplus)
• Improved muscle hardness and vascularity by weeks 4-6
• Fat loss of 2-4 lbs when training in a deficit (likely enhanced nutrient partitioning)
• Strength gains of 5-10% on compound lifts

These are modest compared to RAD-140 or LGD-4033 but come with substantially less hormonal disruption.

Recovery and Training Quality

Multiple reports highlight improved recovery between sessions — reduced DOMS, ability to handle more weekly volume, and better performance on the tail end of training blocks. This is consistent with androgen receptor activation in skeletal muscle improving protein synthesis rates and reducing exercise-induced muscle damage.

Cognitive Effects

An interesting subset of reports mentions subtle cognitive benefits — improved focus, verbal fluidity, and motivation. Androgen receptors exist in the brain, and partial agonism in neural tissue could theoretically modulate dopaminergic and serotonergic function. This remains anecdotal and unquantified.

Female User Reports

AC-262536 is gaining traction among women in the biohacking community. The low androgenic activity (27% of testosterone) makes virilization risk substantially lower than with full agonist SARMs. Women report effective results at 5-10 mg/day without voice changes, acne, or hirsutism. However, individual sensitivity varies, and any woman using AR-active compounds should monitor for early androgenic signs.

Side Effects and Risk Profile

Commonly Reported

• Mild suppression (15-30% testosterone reduction) — recovers within 3-4 weeks post-cycle
• Slight HDL reduction (5-15%) — consistent with all AR agonists
• Temporary fatigue in the final 1-2 weeks of longer cycles (suppression-related)

Rarely Reported

• Hair shedding (less common than RAD-140 or S-23)
• Mood changes (rare, usually at upper dose ranges)
• Mild headaches during the first week (adaptation)

NOT Reported

• Liver toxicity (not methylated, does not appear hepatotoxic at any reported dose)
• Gynecomastia (no aromatization, no estrogenic activity)
• Severe testosterone shutdown (partial agonist ceiling limits this)
• Water retention (no estrogenic or progestogenic activity)

Recommended Blood Work

Pre-cycle and post-cycle (4 weeks after last dose):

• Total and free testosterone
• LH and FSH
• SHBG
• Lipid panel (total cholesterol, HDL, LDL, triglycerides)
• Liver function (AST, ALT)
• Complete blood count

Stacking AC-262536

With Non-Hormonal Compounds

AC-262536 pairs well with compounds that don't add AR pressure:

• GW-0742 or Cardarine — fat oxidation + endurance without additional suppression
• SR-9009 — metabolic enhancement via Rev-ErbA pathway
• MK-677 — GH secretagogue for synergistic lean mass gains without AR-mediated suppression

[Internal Link: /gw-0742/] [Internal Link: /mk-677-ibutamoren/]

With Other SARMs (Advanced)

For advanced users comfortable with moderate suppression:

• AC-262536 + Ostarine — complementary receptor occupancy at different tissues
• AC-262536 + LGD-4033 (low dose) — partial agonist base + small dose of full agonist for additional stimulus

What NOT to Stack With

Stacking AC-262536 with high-dose RAD-140 or S-23 defeats the purpose. If you want aggressive results and accept aggressive suppression, just use the full agonist alone. AC-262536's value proposition is specifically in the mild/moderate space.

Quality and Sourcing: What Matters

The research chemical market has quality variance that can make or break a cycle. For a compound like AC-262536 — which is less commonly manufactured than Ostarine or RAD-140 — sourcing quality is especially critical.

What to Look For

• Third-party HPLC testing: Certificate of analysis showing >98% purity from an independent laboratory (not the manufacturer's own lab)
• Mass spectrometry confirmation: Validates molecular identity, not just purity
• Batch-specific testing: Each production batch tested independently, not just one historic batch
• Proper storage: Peptide-grade desiccant, sealed under nitrogen, stored away from heat and light

Red Flags

• No COA available or "available upon request" with no follow-through
• Prices dramatically below market (synthesis of less-common SARMs costs more, not less)
• Capsule-only formats with no raw powder option (capsules can mask under-dosing)
• Companies that appeared in the last 6 months with no track record

Why It Matters for AC-262536 Specifically

As a less mainstream SARM, AC-262536 has fewer suppliers competing to produce it. This means less price pressure to cut corners — but also less market accountability. A bad batch of Ostarine gets called out quickly because thousands of users have reference points. A bad batch of AC-262536 might go unnoticed because fewer people have baseline experience to compare against.

Always verify your source independently. Blood work response (mild LH suppression within 2-3 weeks) is a rough indicator that the compound is real and dosed correctly.

Legal Status in Canada

AC-262536 is not a controlled substance in Canada. It is not approved as a pharmaceutical or dietary supplement by Health Canada. It is legally available as a research chemical for in-vitro and animal research purposes, similar to other SARMs.

Canadian purchasers can acquire AC-262536 domestically without customs issues. Novo Pharma ships from Canadian warehouses with verified purity certificates and domestic shipping timelines of 2-5 business days to all provinces.

[Internal Link: /ac-262536/]

Frequently Asked Questions

Does AC-262536 require PCT?

For most users at moderate doses (20-30 mg/day for 8-12 weeks), formal pharmaceutical PCT (Nolvadex/Clomid) is generally not required. Suppression is mild and typically recovers within 3-4 weeks naturally. However, blood work is the only reliable way to confirm this. If post-cycle testosterone is suppressed by more than 40%, a mini-PCT protocol is advisable.

How long until I see results from AC-262536?

Expect subtle improvements in training quality and recovery by week 2-3. Visual body composition changes become noticeable around weeks 4-6. Full cycle results are assessed at weeks 8-12. AC-262536 is not a dramatic compound — it's a gradual optimizer.

Is AC-262536 safe for long-term use?

No SARM has established long-term safety data in humans. AC-262536's partial agonist profile theoretically reduces risk compared to full agonists, but "reduced risk" is not "no risk." Cycling (8-12 weeks on, 4-8 weeks off minimum) is the community standard approach to risk mitigation.

Can women use AC-262536?

Yes, with appropriate caution. The low androgenic activity makes it one of the more female-friendly SARMs. Women typically report good results at 5-10 mg/day without virilization. However, individual sensitivity to androgens varies significantly among women, and any early signs of virilization should prompt immediate discontinuation.

Will AC-262536 show up on a drug test?

Standard workplace drug panels do not screen for SARMs. However, WADA-level athletic testing can detect AC-262536 and its metabolites. If you are subject to anti-doping testing in any sport, assume all SARMs are detectable.

The Bigger Picture: Why Partial Agonists Matter

The SARMs field has been dominated by compounds that push toward maximal androgen receptor activation — LGD-4033, RAD-140, S-23. The underlying assumption has been "stronger is better." But for a large segment of users — those who want optimization without disruption, maintenance without shutdown, enhancement without recovery periods — partial agonists like AC-262536 represent a philosophically different approach.

You don't always need a sledgehammer. Sometimes a precision tool that leaves the rest of your system intact produces better long-term outcomes. AC-262536 is that tool.

Conclusion

AC-262536 occupies a unique position in the SARM landscape — a partial agonist that delivers meaningful anabolic signaling with substantially less hormonal disruption than full agonists. It's not the compound for users chasing maximum hypertrophy at any cost. It's the compound for those who want a better risk-to-reward ratio, who value keeping their hormonal system relatively intact, and who think in terms of sustainable optimization rather than peak-and-crash cycles.

As more users share blood work and results, expect AC-262536 to move from underground curiosity to mainstream SARM option. The pharmacology supports it. The early reports support it. The demand for milder, smarter compounds is only growing.

Novo Pharma carries third-party tested AC-262536 with full purity documentation, available for Canadian researchers with fast domestic shipping.

[Internal Link: /ac-262536/]

---

References:

1. Piu F, et al. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. J Steroid Biochem Mol Biol. 2008;109(1-2):129-137.
2. Acadia Pharmaceuticals. AC-262536: A novel nonsteroidal selective androgen receptor modulator. Poster presentation, Endocrine Society Annual Meeting. 2007.
3. Narayanan R, et al. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008;6:e010.
4. Dalton JT, et al. Discovery of nonsteroidal androgens. Biochem Biophys Res Commun. 1998;244(1):1-4.
5. Zhang X, et al. Tissue selectivity of SARMs: dissociation of anabolic and androgenic activities. Expert Opin Ther Targets. 2009;13(2):193-204.
6. Solomon ZJ, et al. Selective androgen receptor modulators: current knowledge and clinical applications. Sex Med Rev. 2019;7(1):84-94.